Penelope J Robinson1, Robin J Bell1, Susan R Davis2. 1. Women's Health Research Program, School of Public Health and Preventive Medicine, Monash University, 99 Commercial Road, Melbourne, Victoria 3004, Australia. 2. Women's Health Research Program, School of Public Health and Preventive Medicine, Monash University, 99 Commercial Road, Melbourne, Victoria 3004, Australia. Electronic address: susan.davis@monash.edu.
Abstract
OBJECTIVE: Whether moderate to severe obesity (body mass index (BMI)≥30 to <40kg/m(2)) contributes to breast cancer recurrence and mortality remains uncertain. SUBJECTS AND METHODS: 1199 women, recruited within 12 months of their diagnosis of hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) invasive breast cancer completed an enrolment questionnaire and an annual follow-up questionnaire every 12 months for another 5 years. The impact of obesity on time to either local or distant recurrence or new breast cancer, or death due to breast cancer was determined by Cox regression. Women in the most extreme categories of BMI (<18.5 and ≥40) were excluded from the analysis. RESULTS: Of the 1155 included women, mean age, 58.4±11.6 years, 53.8% had Stage 1 disease and 88.9% received oral adjuvant endocrine therapy (OAET) within 2 years of diagnosis. The likelihood of an event was significantly associated with moderate to severe obesity (HR=1.71, 95%CI, 1.12-2.62, p=0.014), disease beyond Stage 1 (HR=2.87, 95% CI 1.73-4.75, p<0.001), OAET (HR=0.26, 95%CI 0.14-0.46, p<0.001), mastectomy (HR=3.28, 95%CI 1.98-5.44, p<0.001) and radiotherapy (HR=2.12, 95%CI 1.24-3.63, p=0.006). For Stage 1 disease, only moderate to severe obesity (HR 3.23, 95%CI 1.48-7.03, p=0.003) and OAET use (HR 0.41, 95%CI 0.17-0.98, p=0.046) were significantly associated with an event. CONCLUSION: Moderate to severe obesity is associated with a poorer invasive breast cancer prognosis; this is also true for women with Stage 1 disease, and is independent of age and treatment.
OBJECTIVE: Whether moderate to severe obesity (body mass index (BMI)≥30 to <40kg/m(2)) contributes to breast cancer recurrence and mortality remains uncertain. SUBJECTS AND METHODS: 1199 women, recruited within 12 months of their diagnosis of hormone receptor positive (HR+), humanepidermal growth factor receptor 2 negative (HER2-) invasive breast cancer completed an enrolment questionnaire and an annual follow-up questionnaire every 12 months for another 5 years. The impact of obesity on time to either local or distant recurrence or new breast cancer, or death due to breast cancer was determined by Cox regression. Women in the most extreme categories of BMI (<18.5 and ≥40) were excluded from the analysis. RESULTS: Of the 1155 included women, mean age, 58.4±11.6 years, 53.8% had Stage 1 disease and 88.9% received oral adjuvant endocrine therapy (OAET) within 2 years of diagnosis. The likelihood of an event was significantly associated with moderate to severe obesity (HR=1.71, 95%CI, 1.12-2.62, p=0.014), disease beyond Stage 1 (HR=2.87, 95% CI 1.73-4.75, p<0.001), OAET (HR=0.26, 95%CI 0.14-0.46, p<0.001), mastectomy (HR=3.28, 95%CI 1.98-5.44, p<0.001) and radiotherapy (HR=2.12, 95%CI 1.24-3.63, p=0.006). For Stage 1 disease, only moderate to severe obesity (HR 3.23, 95%CI 1.48-7.03, p=0.003) and OAET use (HR 0.41, 95%CI 0.17-0.98, p=0.046) were significantly associated with an event. CONCLUSION: Moderate to severe obesity is associated with a poorer invasive breast cancer prognosis; this is also true for women with Stage 1 disease, and is independent of age and treatment.
Authors: Xuezheng Sun; Hazel B Nichols; Whitney Robinson; Mark E Sherman; Andrew F Olshan; Melissa A Troester Journal: Cancer Causes Control Date: 2015-10-01 Impact factor: 2.506
Authors: Elizabeth M Cespedes Feliciano; Marilyn L Kwan; Lawrence H Kushi; Wendy Y Chen; Erin K Weltzien; Adrienne L Castillo; Carol Sweeney; Philip S Bernard; Bette J Caan Journal: Cancer Date: 2017-03-13 Impact factor: 6.860
Authors: Rainer J Klement; Petra S Koebrunner; Kelley Krage; Michael M Weigel; Reinhart A Sweeney Journal: Med Oncol Date: 2020-11-28 Impact factor: 3.064
Authors: Marco Gallo; Valerio Adinolfi; Viola Barucca; Natalie Prinzi; Valerio Renzelli; Luigi Barrea; Paola Di Giacinto; Rosaria Maddalena Ruggeri; Franz Sesti; Emanuela Arvat; Roberto Baldelli; Emanuela Arvat; Annamaria Colao; Andrea Isidori; Andrea Lenzi; Roberto Baldell; M Albertelli; D Attala; A Bianchi; A Di Sarno; T Feola; G Mazziotti; A Nervo; C Pozza; G Puliani; P Razzore; S Ramponi; S Ricciardi; L Rizza; F Rota; E Sbardella; M C Zatelli Journal: Rev Endocr Metab Disord Date: 2020-10-06 Impact factor: 6.514